MXPA02001373A - Utilizacion de agentes antagonistas del cgrp en inhbidores de la liberacion del cgrp para combatir sofocos menopausicos.. - Google Patents

Utilizacion de agentes antagonistas del cgrp en inhbidores de la liberacion del cgrp para combatir sofocos menopausicos..

Info

Publication number
MXPA02001373A
MXPA02001373A MXPA02001373A MXPA02001373A MXPA02001373A MX PA02001373 A MXPA02001373 A MX PA02001373A MX PA02001373 A MXPA02001373 A MX PA02001373A MX PA02001373 A MXPA02001373 A MX PA02001373A MX PA02001373 A MXPA02001373 A MX PA02001373A
Authority
MX
Mexico
Prior art keywords
cgrp
release inhibitors
hot flashes
antagonists
menopausal hot
Prior art date
Application number
MXPA02001373A
Other languages
English (en)
Inventor
Wolfgang Eberlein
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA02001373A publication Critical patent/MXPA02001373A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/22—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of calcitonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

El invento se refiere a la utilizacion de agentes antagonistas del CGRP e inhibidores de la liberacion del CGRP para combatir los sofocos menopausicos, asi como correspondientes medicamentos, que como sustancia activa contienen uno o varios antagonistas del CGRP y/o inhibidores de la liberacion del CGRP, y su preparacion.
MXPA02001373A 1999-08-10 2000-08-05 Utilizacion de agentes antagonistas del cgrp en inhbidores de la liberacion del cgrp para combatir sofocos menopausicos.. MXPA02001373A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19937304A DE19937304C2 (de) 1999-08-10 1999-08-10 Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
PCT/EP2000/007613 WO2001010425A2 (de) 1999-08-10 2000-08-05 Verwendung von cgrp-antagonisten und cgrp-release-hemmern zur bekämpfung menopausaler hitzewallungen

Publications (1)

Publication Number Publication Date
MXPA02001373A true MXPA02001373A (es) 2002-07-30

Family

ID=7917551

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02001373A MXPA02001373A (es) 1999-08-10 2000-08-05 Utilizacion de agentes antagonistas del cgrp en inhbidores de la liberacion del cgrp para combatir sofocos menopausicos..

Country Status (32)

Country Link
EP (1) EP1207884B1 (es)
JP (1) JP2003506403A (es)
KR (1) KR100713573B1 (es)
CN (1) CN1166361C (es)
AR (1) AR025078A1 (es)
AT (1) ATE281168T1 (es)
AU (1) AU777709B2 (es)
BG (1) BG65366B1 (es)
BR (1) BR0013009A (es)
CA (1) CA2378428C (es)
CZ (1) CZ300513B6 (es)
DE (2) DE19937304C2 (es)
EA (1) EA007531B1 (es)
EE (1) EE04928B1 (es)
ES (1) ES2231243T3 (es)
HK (1) HK1046854B (es)
HR (1) HRP20020117A2 (es)
HU (1) HUP0202397A3 (es)
IL (1) IL148057A (es)
MX (1) MXPA02001373A (es)
MY (1) MY129668A (es)
NO (1) NO20020605L (es)
NZ (1) NZ517367A (es)
PL (1) PL198483B1 (es)
PT (1) PT1207884E (es)
SK (1) SK285587B6 (es)
TR (1) TR200200359T2 (es)
TW (1) TWI285550B (es)
UA (1) UA73137C2 (es)
WO (1) WO2001010425A2 (es)
YU (1) YU8302A (es)
ZA (1) ZA200200997B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE10139410A1 (de) * 2001-08-17 2003-02-27 Boehringer Ingelheim Pharma Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
US7115609B2 (en) 2001-12-12 2006-10-03 Eli Lilly And Company Alanyl-piperidine heterocyclic derivatives useful against cardiovascular diseases
DE10206770A1 (de) * 2002-02-19 2003-08-28 Boehringer Ingelheim Pharma Verfahren zur Herstellung eines Pulverinhalativums enthaltend ein Salz des CGRP-Antagonisten BIBN4096
US6900317B2 (en) 2002-02-19 2005-05-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Salts of the CGRP antagonist BIBN4096 and inhalable powdered medicaments containing them
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
DE10227294A1 (de) * 2002-06-19 2004-01-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg Zubereitungen zur intranasalen Applikation ausgewählter, von Aminosäuren abgeleiteter CGRP-Antagonisten sowie Verfahren zu deren Herstellung
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250080A1 (de) * 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE10300973A1 (de) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP1648466A1 (en) * 2003-07-07 2006-04-26 Boehringer Ingelheim International GmbH Use of cgrp antagonists in treatment and prevention of hot flushes in prostate cancer patients
AU2004259675A1 (en) * 2003-07-15 2005-02-03 Merck & Co., Inc. Hydroxypyridine CGRP receptor antagonists
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
DE102004015723A1 (de) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004019492A1 (de) * 2004-04-22 2005-11-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7696195B2 (en) 2004-04-22 2010-04-13 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
DE102004063755A1 (de) * 2004-12-29 2006-07-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs
DE102004063752A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen
US7491717B2 (en) 2005-03-23 2009-02-17 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
EP1770091A1 (de) 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7439237B2 (en) 2005-04-15 2008-10-21 Boehringer Ingelheim International Gmbh Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69601765T2 (de) * 1995-09-07 1999-07-08 Oreal Extrakt von Iridaceen und Zusammensetzungen, die ihn enthalten
US5910482A (en) * 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US5710024A (en) * 1996-07-23 1998-01-20 Smithkline Beecham Corporation Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
EE04375B1 (et) * 1996-09-10 2004-10-15 Dr. Karl Thomae Gmbh Modifitseeritud aminohapped, neid ühendeid sisaldavad ravimid ja nende valmistamise meetod
DE19911039A1 (de) * 1999-03-12 2000-09-14 Boehringer Ingelheim Pharma Abgewandelte Aminosäureamide, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Also Published As

Publication number Publication date
AU6992800A (en) 2001-03-05
BG106391A (en) 2002-09-30
YU8302A (sh) 2004-12-31
PL364049A1 (en) 2004-12-13
EE200200061A (et) 2003-04-15
HK1046854B (zh) 2005-02-25
PL198483B1 (pl) 2008-06-30
BG65366B1 (bg) 2008-04-30
NO20020605D0 (no) 2002-02-07
DE19937304A1 (de) 2001-03-15
EP1207884B1 (de) 2004-11-03
JP2003506403A (ja) 2003-02-18
ATE281168T1 (de) 2004-11-15
AR025078A1 (es) 2002-11-06
CN1370069A (zh) 2002-09-18
BR0013009A (pt) 2002-04-30
NO20020605L (no) 2002-02-07
WO2001010425A2 (de) 2001-02-15
SK1972002A3 (en) 2002-06-04
WO2001010425A3 (de) 2002-02-07
HUP0202397A3 (en) 2006-07-28
CZ300513B6 (cs) 2009-06-03
UA73137C2 (en) 2005-06-15
AU777709B2 (en) 2004-10-28
DE19937304C2 (de) 2003-08-21
IL148057A (en) 2008-04-13
PT1207884E (pt) 2004-12-31
CA2378428A1 (en) 2001-02-15
EA200200207A1 (ru) 2002-08-29
ZA200200997B (en) 2002-10-30
EE04928B1 (et) 2007-12-17
SK285587B6 (sk) 2007-04-05
KR20020016947A (ko) 2002-03-06
ES2231243T3 (es) 2005-05-16
TR200200359T2 (tr) 2002-05-21
DE50008527D1 (de) 2004-12-09
CZ2002497A3 (cs) 2002-06-12
EP1207884A2 (de) 2002-05-29
TWI285550B (en) 2007-08-21
MY129668A (en) 2007-04-30
HRP20020117A2 (en) 2003-10-31
EA007531B1 (ru) 2006-10-27
IL148057A0 (en) 2002-09-12
HK1046854A1 (en) 2003-01-30
NZ517367A (en) 2004-09-24
HUP0202397A2 (en) 2002-10-28
CA2378428C (en) 2009-10-20
KR100713573B1 (ko) 2007-05-02
CN1166361C (zh) 2004-09-15

Similar Documents

Publication Publication Date Title
MXPA02001373A (es) Utilizacion de agentes antagonistas del cgrp en inhbidores de la liberacion del cgrp para combatir sofocos menopausicos..
MXPA01010588A (es) Medicamentos que contienen de la cinasa humana regulada por el volumen celular h-sgk.
DE60112609D1 (en) Pyrazolopyridine
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
AU7743001A (en) Cyclopentanoindoles, compositions containing such compounds and methods of treatment
AU3652102A (en) Compounds and their uses
TWI256389B (en) Novel hPPAR delta agonists and pharmaceutical compositions comprising the same
MX9702070A (es) Nuevos inhibidores de resorcion osea y antagonistas de receptor de vitronectina.
MY122391A (en) Piperazine derivatives as 5-ht1b antagonists
DE60112330D1 (en) Pyrazolopyridinderivate
HK1030218A1 (en) Novel 2-(iminomethyl)amino-phenyl derivatives, preparation, application as medicines and compositions containing same.
EP1244452A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
TR200002896T2 (tr) Kalsilitik Bileşimler
AU6469401A (en) Pharmaceutically active compounds and methods of use
BG105761A (en) Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents
IL157065A0 (en) 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof
MXPA03001455A (es) Compuestos de pirazol, composiciones farmaceuticas y metodos para modular o inhibir la actividad del amiloide-beta-peptido asociado a reticulo endoplasmico y l-3-hidroxiacil-coa-deshidrogenasa.
IL144199A0 (en) Novel bretylium compositions and kits, and their use in preventing and treating cardiovascular conditions
IL137489A0 (en) Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway
EP1246619A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
DE60201074D1 (en) Pyrazolopyridinderivate
MXPA04004090A (es) Compuestos substituidos de 1h-quinolin-2-ona.
AU2576901A (en) Agents and methods for the treatment of proliferative diseases
YU26001A (sh) Derivati ureidopiperidina kao selektivni antagonisti ljudskih nk3 receptora
PL359727A1 (en) Crystalline pharmaceutical

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration